SCHEMBL25411095

SCHEMBL25411095

Fc1nc(Cl)ccc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.41
CYP11B1 P15538 1/20 0.41
KCNQ3 O43525 2/20 0.35
KCNQ2 O43526 2/20 0.35
KCNE1 P15382 2/20 0.35
KCNQ1 P51787 2/20 0.35
XPO1 O14980 3/20 0.34
ADRB2 P07550 1/20 0.34
GRM2 Q14416 4/20 0.33
PIK3CD O00329 1/20 0.33
ALDH1A1 P00352 2/20 0.32
NOTUM Q6P988 4/20 0.32
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31
KDM4E B2RXH2 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31361149 0.83 CYP11B1 (0.33) CYP11B2CYP11B1
SCHEMBL21718901 0.80 CYP3A4 (0.30) CYP11B2CYP11B1CYP3A4TSHR
SCHEMBL855349 0.79 XPO1 (0.46) CYP11B2CYP11B1XPO1ADRB2GRM2
SCHEMBL29388275 0.79 XPO1 (0.46) CYP11B2CYP11B1XPO1ADRB2GRM2
SCHEMBL11272404 0.77 KDM4E (0.46) PIK3CDALDH1A1TSHRKDM4EKMT2A
SCHEMBL23850283 0.77 XPO1 (0.41) CYP11B2CYP11B1KCNQ3KCNQ2KCNE1
SCHEMBL3509516 0.77 AR (0.33) KMT2A
SCHEMBL10681454 0.76 CYP11B2 (0.33) CYP11B2CYP11B1
SCHEMBL29518793 0.76 CYP11B2 (0.33) CYP11B2CYP11B1
SCHEMBL1479479 0.76 CYP11B1 (0.37) CYP11B2CYP11B1KCNQ3KCNQ2KCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746965-A1 BENZIMIDAZOLES AS SIK-ACTIVITY MODULATORS F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
WO-2025017041-A1 BENZIMIDAZOLES AS SIK-ACTIVITY MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2025-01-23 WO disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 US disclosed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP disclosed
CN-116323557-A Cyclobutylamide monoacylglycerol lipase modulators 詹森药业有限公司 2023-06-23 CN disclosed
WO-2022063784-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 WO disclosed
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP CYP11B2 649/4885CYP11B1 456/4885KCNQ3 1261/4885
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP CYP11B2 643/4885CYP11B1 454/4885KCNQ3 1271/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP CYP11B2 643/4885CYP11B1 454/4885KCNQ3 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.